Literature DB >> 19509543

Prevalence of antitumor antibodies in laying hen model of human ovarian cancer.

Animesh Barua1, Seby L Edassery, Pincas Bitterman, Jacques S Abramowicz, Angela L Dirks, Janice M Bahr, Dale B Hales, Michael J Bradaric, Judith L Luborsky.   

Abstract

Antitumor antibodies are associated with tumors in human cancers. There is relatively little information on the timing and progression of antibody response to tumors. The objective of the study was to determine if spontaneous ovarian cancer in the egg-laying hen is associated with antitumor antibodies. Antibodies were detected by immunoassay and immunoblotting using proteins from normal ovary and ovarian tumors. Candidate antigens were identified by mass spectrometry of immunoreactive spots cut from 2-dimensional gels and Western blot. Antitumor (serum reacting against tumor ovarian extract) and antiovarian (serum reacting against normal ovarian extract) antibodies were significantly associated with ovarian cancer (67%; P <or= 0.001) compared with normal control hens. Hens with abnormal histology but no gross tumor had antitumor antibodies (63%; P <or= 0.025) but not antiovarian antibodies. There were common as well as different immunoreactions against normal ovary and homologous and heterologous tumor proteins in 2-dimensional Western blots. The candidate antigens included those commonly associated with human cancers and other diseases such as vimentin, apolipoprotein A1, Annexin II, enolase, DJ-1, and so on. The results suggest that antitumor antibodies are associated with ovarian cancer in hens, similar to human ovarian cancer. The egg-laying hen may be a model for understanding the antitumor humoral immune response, particularly at early tumor stages that are not readily accessible in human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509543      PMCID: PMC2782776          DOI: 10.1111/IGC.0b013e3181a39db1

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  45 in total

1.  Ovarian autoimmunity in relation to egg production in laying hens.

Authors:  A Barua; Y Yoshimura
Journal:  Reproduction       Date:  2001-01       Impact factor: 3.906

2.  CA125 expression in spontaneous ovarian adenocarcinomas from laying hens.

Authors:  Emily Jackson; Ken Anderson; Chris Ashwell; James Petitte; Paul E Mozdziak
Journal:  Gynecol Oncol       Date:  2006-08-30       Impact factor: 5.482

3.  Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus domesticus model of ovarian cancer.

Authors:  M E Urick; P A Johnson
Journal:  Gynecol Oncol       Date:  2006-06-22       Impact factor: 5.482

4.  Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response.

Authors:  H Naora; F J Montz; C Y Chai; R B Roden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

5.  Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention.

Authors:  C Rodríguez-Burford; M N Barnes; W Berry; E E Partridge; W E Grizzle
Journal:  Gynecol Oncol       Date:  2001-06       Impact factor: 5.482

Review 6.  Role of Annexin-II in GI cancers: interaction with gastrins/progastrins.

Authors:  Pomila Singh
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

Review 7.  Disease association, origin, and clinical relevance of autoantibodies to the glycolytic enzyme enolase.

Authors:  V M Gitlits; B H Toh; J W Sentry
Journal:  J Investig Med       Date:  2001-03       Impact factor: 2.895

8.  Detection of ovarian tumors in chicken by sonography: a step toward early diagnosis in humans?

Authors:  Animesh Barua; Jacques S Abramowicz; Janice M Bahr; Pincas Bitterman; Angela Dirks; Keith A Holub; Eyal Sheiner; Michael J Bradaric; Seby L Edassery; Judith L Luborsky
Journal:  J Ultrasound Med       Date:  2007-07       Impact factor: 2.153

9.  Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.

Authors:  Animesh Barua; Michael J Bradaric; Tewabe Kebede; Sara Espionosa; Seby L Edassery; Pincas Bitterman; Jacob Rotmensch; Judith L Luborsky
Journal:  Am J Reprod Immunol       Date:  2007-04       Impact factor: 3.886

10.  Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer.

Authors:  Ping He; Tetsuji Naka; Satoshi Serada; Minoru Fujimoto; Toshio Tanaka; Shoji Hashimoto; Yoshihito Shima; Tomoki Yamadori; Hidekazu Suzuki; Tomonori Hirashima; Kaoru Matsui; Hiroyuki Shiono; Meinoshin Okumura; Toshiro Nishida; Isao Tachibana; Naoko Norioka; Shigemi Norioka; Ichiro Kawase
Journal:  Cancer Sci       Date:  2007-05-15       Impact factor: 6.716

View more
  12 in total

1.  Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure.

Authors:  Seby L Edassery; Seerin V Shatavi; Jeremy P Kunkel; Charles Hauer; Cosima Brucker; Krishna Penumatsa; Yi Yu; James A Dias; Judith L Luborsky
Journal:  Fertil Steril       Date:  2010-06-01       Impact factor: 7.329

Review 2.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

3.  Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer.

Authors:  Animesh Barua; Aparna Yellapa; Janice M Bahr; Jacques S Abramowicz; Seby L Edassery; Sanjib Basu; Jacob Rotmensch; Pincas Bitterman
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

4.  Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer.

Authors:  Mohammad Faisal Khan; Janice M Bahr; Aparna Yellapa; Pincas Bitterman; Jacques S Abramowicz; Seby L Edassery; Sanjib Basu; Jacob Rotmensch; Animesh Barua
Journal:  Transl Oncol       Date:  2012-04-01       Impact factor: 4.243

5.  Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.

Authors:  Yi Yu-Rice; Seby L Edassery; Nicole Urban; Ingegerd Hellstrom; Karl Erik Hellstrom; Youping Deng; Yan Li; Judith L Luborsky
Journal:  Reproduction       Date:  2016-12-13       Impact factor: 3.906

6.  Towards an animal model of ovarian cancer: cataloging chicken blood proteins using combinatorial peptide ligand libraries coupled with shotgun proteomic analysis for translational research.

Authors:  Yingying Ma; Zeyu Sun; Ricardo de Matos; Jing Zhang; Kunle Odunsi; Biaoyang Lin
Journal:  OMICS       Date:  2014-03-24

7.  Sphingosine-1 phosphate receptor (S1p1), a critical receptor controlling human lymphocyte trafficking, is expressed in hen and human ovaries and ovarian tumors.

Authors:  Michael J Bradaric; Animesh Barua; Krishna Penumatsa; Yu Yi; Seby L Edassery; Sameer Sharma; Jacques S Abramowicz; Janice M Bahr; Judith L Luborsky
Journal:  J Ovarian Res       Date:  2011-02-28       Impact factor: 4.234

8.  The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors.

Authors:  Yi Yu; Seby L Edassery; Animesh Barua; Jacques S Abramowicz; Janice M Bahr; Ingegerd Hellstrom; Judith L Luborsky
Journal:  J Ovarian Res       Date:  2011-07-29       Impact factor: 4.234

9.  Three are better than one: plasminogen receptors as cancer theranostic targets.

Authors:  Patrizia Ceruti; Moitza Principe; Michela Capello; Paola Cappello; Francesco Novelli
Journal:  Exp Hematol Oncol       Date:  2013-04-17

10.  Immune cells in the normal ovary and spontaneous ovarian tumors in the laying hen (Gallus domesticus) model of human ovarian cancer.

Authors:  Michael J Bradaric; Krishna Penumatsa; Animesh Barua; Seby L Edassery; Yi Yu; Jacques S Abramowicz; Janice M Bahr; Judith L Luborsky
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.